Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023

BUY
$0.12 - $0.69 $0 - $3
5 Added 0.65%
772 $0
Q4 2022

Feb 13, 2023

SELL
$0.23 - $0.34 $113 - $167
-494 Reduced 39.18%
767 $0
Q3 2022

Nov 14, 2022

SELL
$0.35 - $0.72 $5 - $10
-15 Reduced 1.18%
1,261 $0
Q2 2022

Aug 12, 2022

BUY
$0.38 - $2.58 $274 - $1,862
722 Added 130.32%
1,276 $0
Q1 2022

May 16, 2022

BUY
$2.27 - $3.62 $456 - $727
201 Added 56.94%
554 $2,000
Q4 2021

Feb 14, 2022

BUY
$2.11 - $3.0 $211 - $300
100 Added 39.53%
353 $1,000
Q3 2021

Nov 15, 2021

SELL
$2.21 - $2.89 $33 - $43
-15 Reduced 5.6%
253 $1,000
Q2 2021

Aug 16, 2021

SELL
$2.39 - $3.5 $27,528 - $40,313
-11,518 Reduced 97.73%
268 $1,000
Q1 2021

May 13, 2021

SELL
$2.86 - $4.33 $112,083 - $169,692
-39,190 Reduced 76.88%
11,786 $35,000
Q4 2020

Feb 09, 2021

BUY
$2.93 - $4.3 $24,902 - $36,545
8,499 Added 20.01%
50,976 $177,000
Q3 2020

Nov 05, 2020

SELL
$3.05 - $4.99 $14,862 - $24,316
-4,873 Reduced 10.29%
42,477 $143,000
Q2 2020

Aug 13, 2020

BUY
$1.99 - $4.4 $93,888 - $207,592
47,180 Added 27752.94%
47,350 $198,000
Q1 2020

May 14, 2020

BUY
$1.81 - $5.03 $307 - $855
170 New
170 $0

About Aptinyx Inc.


  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.